A PhII flop trig­gers an ug­ly rout for mi­cro-cap biotech Aridis; Gen­fit CEO pass­es ba­ton to suc­ces­sor

→ Mi­cro-cap biotech Aridis Phar­ma­ceu­ti­cals $ARDS got ham­mered this morn­ing as in­ves­ti­ga­tors re­vealed that one of its clin­i­cal-stage drugs failed a mid-stage study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER